Vitamin K antagonist

Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED ENDPOINT EVALUATION (PROBE) PARALLEL GROUP STUDY COMPARING EDOXABAN VS. VKA IN SUBJECTS UNDERGOING CATHETER ABLATION OF NON-VALVULAR ATRIAL FIBRILLATION

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

Patient Convenience Study- NIS RELATE

Long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism

Registration of Idarucizumab for Patients with IntraCranial Hemorrhage